Larimar Therapeutics Inc (LRMR)

Jun 04, 2025

ProShare Advisors LLC Purchases Shares of 14,870 Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jun 04, 2025

May 23, 2025

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN

May 23, 2025

May 23, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa

May 23, 2025

May 22, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com

May 22, 2025

May 18, 2025

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo

May 18, 2025

May 13, 2025

Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

May 13, 2025

May 06, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

May 06, 2025

May 04, 2025

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks

May 04, 2025

May 02, 2025

Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

May 02, 2025

May 02, 2025

The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News

May 02, 2025

May 02, 2025

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail

May 02, 2025

May 02, 2025

Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World

May 02, 2025

May 01, 2025

LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com

May 01, 2025

May 01, 2025

Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com

May 01, 2025

Apr 30, 2025

Larimar: Q1 Earnings Snapshot - MySA

Apr 30, 2025

Apr 30, 2025

Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView

Apr 30, 2025

Apr 30, 2025

Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX

Apr 30, 2025

Apr 30, 2025

Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus

Apr 30, 2025

Apr 30, 2025

Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

Apr 30, 2025

Apr 30, 2025

Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan

Apr 30, 2025

Apr 27, 2025

Larimar Therapeutics awards key executives performance-based stock - MSN

Apr 27, 2025

Apr 23, 2025

Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX

Apr 23, 2025

Apr 23, 2025

Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com

Apr 23, 2025

Apr 23, 2025

Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News

Apr 23, 2025

Apr 22, 2025

The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com

Apr 22, 2025

Apr 04, 2025

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha

Apr 04, 2025

Apr 03, 2025

An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com

Apr 03, 2025

Apr 01, 2025

Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News

Apr 01, 2025

Mar 31, 2025

Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat

Mar 31, 2025

Mar 28, 2025

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN

Mar 28, 2025

Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World

Mar 26, 2025

Mar 26, 2025

HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World

Mar 26, 2025

Mar 26, 2025

Larimar Therapeutics Inc (NASDAQ: LRMR) Shares Might Go Down -73.01% This Year - Marketing Sentinel

Mar 26, 2025

Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World

Mar 26, 2025

Mar 25, 2025

Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK

Mar 25, 2025

Mar 25, 2025

Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks

Mar 25, 2025

Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia

Mar 24, 2025

Mar 24, 2025

Larimar: Q4 Earnings Snapshot - mySA

Mar 24, 2025

Mar 24, 2025

Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener

Mar 24, 2025

Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval - Investing.com India

Mar 24, 2025

Mar 24, 2025

Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener

Mar 24, 2025

Mar 24, 2025

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment - Stock Titan

Mar 24, 2025

Mar 14, 2025

Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView

Mar 14, 2025